Literature DB >> 21097678

NSAID inhibition of prostate cancer cell migration is mediated by Nag-1 Induction via the p38 MAPK-p75(NTR) pathway.

Shehla Wynne1, Daniel Djakiew.   

Abstract

The nonsteroidal anti-inflammatory drugs (NSAID) R-flurbiprofen and ibuprofen have been shown to induce expression of p75(NTR) (neurotrophin receptor) in prostate cancer cell lines. p75(NTR), a tumor necrosis factor receptor superfamily member, is a proapoptotic protein that functions as a tumor suppressor in the human prostate. Expression of p75(NTR) is lost as prostate cancer progresses and is minimal in several metastatic prostate cancer cell lines. NSAIDs induce p75(NTR) through activation of the p38 mitogen-activated protein kinase (MAPK) pathway, with a concomitant decrease in cell survival. Here, we show that treatment with R-flurbiprofen and ibuprofen induces expression of the NSAID-activated gene-1 (Nag-1) protein, a divergent member of the TGF beta (TGF-β) family, in PC-3 cells. Using the selective pharmacologic inhibitor of p38 MAPK, SB202190, and p38 MAPK-specific siRNA (small interfering RNA), we show that Nag-1 induction following NSAID treatment is mediated by the p38 MAPK pathway. p75(NTR)-specific siRNA pretreatment shows that Nag-1 induction by NSAIDs is downstream of p75(NTR) induction. Decreased survival of NSAID-treated cells is rescued by p75(NTR)-specific siRNA but not by Nag-1 siRNA. Transwell chamber and in vitro wound healing assays demonstrate decreased cell migration upon NSAID treatment. Pretreatment of PC-3 cells with p75(NTR) and Nag-1-specific siRNA shows that NSAID inhibition of cell migration is mediated by Nag-1 and p75(NTR). These results demonstrate a role for Nag-1 in NSAID inhibition of cell migration, but not survival. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097678      PMCID: PMC3003770          DOI: 10.1158/1541-7786.MCR-10-0342

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  38 in total

1.  Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities.

Authors:  S J Baek; K S Kim; J B Nixon; L C Wilson; T E Eling
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner.

Authors:  Seong-Ho Lee; Kiyoshi Yamaguchi; Jong-Sik Kim; Thomas E Eling; Stephen Safe; Yeonhwa Park; Seung Joon Baek
Journal:  Carcinogenesis       Date:  2005-11-14       Impact factor: 4.944

3.  Characterization of a p75(NTR) apoptotic signaling pathway using a novel cellular model.

Authors:  X Wang; J H Bauer; Y Li; Z Shao; F S Zetoune; E Cattaneo; C Vincenz
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

4.  Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors.

Authors:  Matias E Valsecchi; Sherry C Pomerantz; Rebecca Jaslow; William Tester
Journal:  Clin Breast Cancer       Date:  2009-11       Impact factor: 3.225

5.  Apoptosis induced by p75NTR overexpression requires Jun kinase-dependent phosphorylation of Bad.

Authors:  Asha L Bhakar; Jenny L Howell; Christine E Paul; Amir H Salehi; Esther B E Becker; Farid Said; Azad Bonni; Philip A Barker
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

6.  3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.

Authors:  Fatima S Khwaja; Shehla Wynne; Isadora Posey; Daniel Djakiew
Journal:  Cancer Prev Res (Phila)       Date:  2009-05-26

7.  Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer.

Authors:  Kyung Hee Lee; Jae-Ryong Kim
Journal:  Oncol Res       Date:  2009       Impact factor: 5.574

8.  R-flurbiprofen reverses multidrug resistance, proliferation and metastasis in gastric cancer cells by p75(NTR) induction.

Authors:  Haifeng Jin; Zhipeng Wang; Lili Liu; Liucun Gao; Li Sun; Xiaohua Li; Hongxi Zhao; Yanglin Pan; Hai Shi; Na Liu; Liu Hong; Jie Liang; Qiong Wu; Zhiping Yang; Kaichun Wu; Daiming Fan
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

9.  A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.

Authors:  Isolda Casanova; Rosa Bosch; Adriana Lasa; Matilde Parreño; María Virtudes Céspedes; Salut Brunet; Josep F Nomdedéu; María Antònia Mangues; Jorge Sierra; Ramon Mangues
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

10.  The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells.

Authors:  Emily J Quann; Fatima Khwaja; Daniel Djakiew
Journal:  Cancer Res       Date:  2007-12-01       Impact factor: 12.701

View more
  24 in total

1.  Fifty years since the discovery of ibuprofen.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2011-12       Impact factor: 4.473

2.  Sevoflurane inhibits invasion and migration of lung cancer cells by inactivating the p38 MAPK signaling pathway.

Authors:  Hua Liang; Miaoning Gu; Chengxiang Yang; Hanbing Wang; Xianjie Wen; Qiaoling Zhou
Journal:  J Anesth       Date:  2012-02-17       Impact factor: 2.078

Review 3.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

Review 4.  COX inhibitors directly alter gene expression: role in cancer prevention?

Authors:  Xingya Wang; Seung Joon Baek; Thomas Eling
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Reduced expression of GDF-15 is associated with atrophic inflammatory lesions of the prostate.

Authors:  James R Lambert; Ramon J Whitson; Kenneth A Iczkowski; Francisco G La Rosa; Maxwell L Smith; R Storey Wilson; Elizabeth E Smith; Kathleen C Torkko; Hamid H Gari; M Scott Lucia
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

Review 6.  The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer.

Authors:  Xingya Wang; Seung Joon Baek; Thomas E Eling
Journal:  Biochem Pharmacol       Date:  2012-12-07       Impact factor: 5.858

7.  R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease.

Authors:  Bruce G Jenkins; Alpaslan Dedeoglu; Isabel Carreras; Ann C McKee; Ji-Kyung Choi; Nurgul Aytan; Neil W Kowall
Journal:  Brain Res       Date:  2013-10-22       Impact factor: 3.252

Review 8.  Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets.

Authors:  Jason L Liggett; Xiaobo Zhang; Thomas E Eling; Seung Joon Baek
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

9.  Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.

Authors:  Jack U Flanagan; Yuliana Yosaatmadja; Rebecca M Teague; Matilda Z L Chai; Andrew P Turnbull; Christopher J Squire
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

10.  A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways.

Authors:  Wanli Deng; Hua Sui; Qiaolin Wang; Nana He; Chunyan Duan; Liang Han; Qi Li; Ming Lu; Shuqin Lv
Journal:  BMC Complement Altern Med       Date:  2013-03-18       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.